Cell & Gene Therapy SWEDEN

The work to establish a partnership for a national coordination function on ATMP is progressing according to plan. We are now introducing **Cell & Gene Therapy SWEDEN** as the name of the partnership.

The establishment is conducted through two synchronized and coordinated projects, one of which has financial support through Swelife/Vinnova. The goal is to create the conditions for competitiveness in terms of patients' access to treatment, the conditions for research and our ability to translate research into product development and production in Sweden. The ambition is that Cell & Gene Therapy SWEDEN has been formed as a consortium, including financing and operational activities during the second half of 2026.

Partners in the work are our seven medical universities, seven university hospitals and seven representatives of biotech, pharmaceuticals and medical technology, who gathered in connection with the conclusion of the Vinnova-supported projects CAMP and the Innovation Environment ATMP2030. The association ATMP Sweden, which is responsible for the website atmpsweden.se has also been connected to the project for strengthened anchoring in the ecosystem, especially as communication support and digital publishing. We see that there are good conditions for Cell & Gene Therapy SWEDEN and Föreningen ATMP Sweden to complement each other through various assignments and their respective partner circles.

1. During the spring, Hannah Karlsson, Uppsala University Hospital has taken on a new role within CGT SWEDEN, as chair of the coordination group. We also welcome Sara Nolbrant, Lund University as project coordinator," says Dag Larsson, who is chairman of the steering group on rotating mandates. We are now gaining momentum to be able to present a financed and unifying activity that makes Sweden more competitive.

Kommenterad [HK1]: chairman

In the future, we will be visible on the web platform www.atmpsweden.se and on LinkedIn.

Contact

- Dag Larsson dag.larsson@lif.se 070-3111727
- Hannah Karlsson hannah.karlsson@akademiska.se
- Sara Nolbrant sara.nolbrant@med.lu.se

The development of Cell & Gene Therapy SWEDEN is led by partner engagement as follows.

- **Steering Group:** Dag Larsson, Lif (ordförande); Martin Bergö, Karolinska institutet; Christina Herder, SwedenBio; Jan Holgerson, Sahlgrenska sjukhuset; Stefan Jovinge, Skånes universitetssjukhus; Eva Tiensuu Janson, Uppsala universitet
- Sara Nolbrant, Lunds universitet (projektkoordinator)
- Elias Uhlin, Föreningen ATMP Sweden (adjungerad)

- **Coordination Group:** Hannah Karlsson, Akademiska sjukhuset (ordförande); Christian Andersson, Sahlgrenska sjukhuset; Petter Björquist, Verigraft; Karin Blomberg, Örebro universitet; Pontus Blomberg, Karolinska universitetssjukhuset; Lindsay Davies, QVance; Gunilla Enblad, Uppsala universitet; Ewa Ellis, Karolinska institutet; Anna Göthlin-Eremo, Universitetssjukhuset Örebro; Per Hammer, Cytiva; Paul Kingham, Umeå universitet; Jessica Martinsson, SwedenBio; Jenny Nyström, Sahlgrenska akademin; Martin Olsson, Lunds universitet; Anna Sandström, AstraZeneca; Lars Skagerlind, Norrlands universitetssjukhus; Marcus Söderberg, Universitetssjukhuset Linköping
-